Perrigo Company plc(PRGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -12.51 | Insider Own | 0.44% | Shs Outstand | 138.7M | Perf Week | -1.68% |
| Market Cap | 2.20B | Forward P/E | 6.62 | EPS next Y | 9.13% | Insider Trans | - | Shs Float | 138.2M | Perf Month | 2.59% |
| Enterprise Value | 5.25B | PEG | - | EPS next Q | 0.51 | Inst Own | 111.27% | Short Float | 17.55% | Perf Quarter | 53.59% |
| Income | -1.73B | P/S | 0.53 | EPS this Y | -20.39% | Inst Trans | 1.74% | Short Ratio | 8.72 | Perf Half Y | 37.68% |
| Sales | 4.14B | P/B | 0.87 | EPS next 5Y | -0.98% | ROA | -19.24% | Short Interest | 24.24M | Perf YTD | 13.65% |
| Book/sh | 18.14 | P/C | 5.49 | EPS past 3/5Y | -114.32% -53.83% | ROE | -48.75% | 52W High | -28.12% ($22.01) | Perf Year | -26.28% |
| Cash/sh | 2.88 | P/FCF | 18.4 | Sales past 3/5Y | -1.5% 0.8% | ROIC | -29.22% | 52W Low | 71.49% ($9.23) | Perf 3Y | -44.61% |
| Dividend Est. | $1.16 (7.3%) | EV/EBITDA | 7.51 | EPS Y/Y TTM | -2138.82% | Gross Margin | 33.32% | Volatility(W/M) | 3.3% 4.18% | Perf 5Y | -64.37% |
| Dividend TTM | 1.16 | EV/Sales | 1.27 | Sales Y/Y TTM | -4.18% | Oper. Margin | 6.42% | ATR (14) | 0.64 | Perf 10Y | -82.56% |
| Dividend Ex-Date | 2026/8/28 | Quick Ratio | 1.32 | EPS Q/Q | 977.8% | Profit Margin | -41.85% | RSI (14) | 56.77 | Recom | 2.67 |
| Dividend Gr. 3/5Y | 3.71% 5.21% | Current Ratio | 2.32 | Sales Q/Q | -3.17% | SMA20 | 3.13% ($15.34) | Beta | 0.72 | Target Price | $15.33 |
| Payout | - | Debt/Eq | 1.37 | Earnings | 2026/11/4 | SMA50 | 8.2% ($14.62) | Rel Volume | 0.54 | Prev Close | $15.96 |
| Employees | 8100 | LT Debt/Eq | 1.36 | EPS/Sales Surpr. | 28.87% 0.72% | SMA200 | 27.31% ($12.43) | Avg Volume(3M) | 2.78M | Price | $15.82 |
| IPO | 1991/12/17 | Option/Short | Yes/Yes | Trades | 13264 | Volume | 1,495,255 | Change | -0.88% |
💊 A global healthcare company that manufactures and sells consumer self-care products. It produces and supplies over-the-counter (OTC) medicines, infant nutrition, and women's health products under its own brands and retailer private labels, supported by a global manufacturing and distribution network. The company has established itself as a healthcare business focused specifically on consumer self-care.
Over the past 1 year, roughly in the middle
28% below its 1-year high.
Traded less than usual. That is 54% of its average volume.
Next earnings report: November 4
8 days to go.
PRGO keeps an operating profit but posts a net loss
Of every $100 in sales, $6.42 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -20.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $53. Peers typically go for $150.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -64.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 7.30% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 111.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 83 in the industry
Based on market cap of $2B.
FAQ
What kind of company is PRGO?
PRGO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PRGO?
The market cap of PRGO is approximately $2.2B, ranking 1,949 within its sector.
Does PRGO pay dividends?
PRGO has a dividend yield of approximately 7.30%, with an annual dividend of $1.16.
What is the 52-week high and low for PRGO?
PRGO has recorded a 52-week high of $22.01 and a low of $9.23.